2015
DOI: 10.4172/2471-2663.1000107
|View full text |Cite
|
Sign up to set email alerts
|

Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents

Abstract: Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic diseases that associated with increased risk for cardiovascular (CV) diseases and newly CV events. Although CV risk assessment is incorporated in primary and secondary prevention strategies to improve morbidity and mortality that are applied in diabetic patient, it is important to stratify individuals at high CV risk not just prior diabetic complication, but at early stages of development of the CV diseases. The aim of the editorial comment… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 72 publications
0
5
0
Order By: Relevance
“…EPCs are mobilized from bone marrow and probably from peripheral tissues upon injury in result in growth factors and inflammatory cytokines [20]. Decreased numerous of circulating EPCs was found a marker of impaired endothelial function and early atherosclerosis [21][22][23][24]. Therefore, increased production of reactive oxygen species, insulin resistance, reduced NO bioavailability have been identified as mediators of tissue injury leading to lowered EPC functionality and reduced angiogenic capacity in vivo [25][26][27].…”
Section: Introductionmentioning
confidence: 97%
“…EPCs are mobilized from bone marrow and probably from peripheral tissues upon injury in result in growth factors and inflammatory cytokines [20]. Decreased numerous of circulating EPCs was found a marker of impaired endothelial function and early atherosclerosis [21][22][23][24]. Therefore, increased production of reactive oxygen species, insulin resistance, reduced NO bioavailability have been identified as mediators of tissue injury leading to lowered EPC functionality and reduced angiogenic capacity in vivo [25][26][27].…”
Section: Introductionmentioning
confidence: 97%
“…The large amount of literature regarding the use of cardiac biomarkers in T2DM detection has accentuated the need of discussing the clinical utility of markers of cardiac biochemical stress, vascular remodeling and low-grade inflammation, such as natriuretic peptides (NPs), galectin-3 (Gal-3), interleukins and growth differentiation factor-15 (GDF-15) [35,36,37]. These biomarkers have been proposed as future candidates of diagnostic or prognostic value in diabetic patients [37].…”
Section: Macrovascular T2dm Complicationsmentioning
confidence: 99%
“…Thus, their role in T2DM progression appears to be strongly controversial. Consequently, the NP system in obese and diabetic patients is not able to mediate a wide spectrum of cardiovascular and metabolic protective effects that involve mechanisms of vasodilation, natriuresis, lipolysis, weight loss, lusitropy, lipid peroxidation, mitochondrial respiration improvement and insulin sensitivity [37]. However, according to contemporary clinical guidelines for heart failure, NPs are recognized as powerful biomarkers for acute coronary syndrome and cardiac cytotoxicity, and they provide more accurate diagnostic and predictive values [38,39].…”
Section: Macrovascular T2dm Complicationsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, contemporary treatment approaches based on improved glycemic control have been exhibited an ability to contribute in decreased CV complications related to T2DM, whereas utilization of modern strategy is higher cost and appears to be economic challenge to the health care system [4][5][6]. In this context, several circulating biomarkers represented differential metabolic profiles, related to vascular complications and predicted CV events may be clinically helpful for risk stratification and individualized treatment for T2DM patients [7,8]. Although various biomarkers (natriuretic peptides, galectin-3, soluble ST2, growth-differentiation factor-15, signature of microRNAs, oxidative stress components, inflammatory cytokines, biomarkers of coagulation and endothelial damage) are widely used as predictors of adverse clinical outcomes in several settings [9][10][11][12], there is concern regarding their role as biological target in T2DM care [8,13].…”
Section: Introductionmentioning
confidence: 99%